Physician profile
Mark E Davis
NPI 1306814678
$721.52
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $180.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $206.37 | 2019-2020 | |
| Novo Nordisk INC | $124.83 | 2019 | |
| Amgen INC. | $49.80 | 2019-2020 | |
| Amarin Pharma, INC. | $44.18 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.11 | 2019 | |
| Melinta Therapeutics, LLC | $36.30 | 2019 | |
| Astellas Pharma US INC | $35.51 | 2019 | |
| Sanofi-Aventis U.S. LLC | $29.62 | 2020 | |
| Novartis Pharmaceuticals Corporation | $26.24 | 2019-2020 | |
| Lilly USA, LLC | $26.01 | 2019 | |
| Avanir Pharmaceuticals, INC. | $24.09 | 2019 | |
| Abbvie INC. | $17.56 | 2019 | |
| Allergan, INC. | $16.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.98 | 2019 | |
| Pfizer INC. | $11.90 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11.22 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.